Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer

Mingwei Chen; Jianfa Li; Chengle Zhuang; Zhiming Cai

doi:10.18632/oncotarget.14945

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer

Mingwei Chen _, Jianfa Li, Chengle Zhuang and Zhiming Cai

PDF | HTML | How to cite

Oncotarget. 2017; 8:28176-28186. https://doi.org/10.18632/oncotarget.14945

Metrics: PDF 2001 views | HTML 3117 views | ?

Abstract

Mingwei Chen1, Jianfa Li2, Chengle Zhuang3, Zhiming Cai2

1Department of Urology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu 322000, Zhejiang, China

2Shantou University Medical College, Shantou 515041, Guangdong, China

3Peking University Shenzhen Hospita, Shenzhen 518036, Guangdong, China

Correspondence to:

Mingwei Chen, email: [email protected]

Keywords: ABHD11-AS1, bladder cancer, lncRNAs, proliferation, migration

Received: October 09, 2016 Accepted: January 10, 2017 Published: February 01, 2017

ABSTRACT

Bladder cancer is one of the most common urothelial tumors worldwide. While there are some progresses on early bladder cancer detection, patients’ mortalities have not been changed significantly. So it is important to get further understanding the mechanism involved in the development and progression of bladder cancer. Long non-coding RNAs play important regulatory roles in a variety of biological processes ranging from gene regulation, cellular differentiation to tumorigenesis. Previous literatures reported that lncRNA ABHD11 Antisense RNA 1 (ABHD11-AS1) (Organism: Homo sapiens) was highly expressed in gastric cancer. Inspired by these observations, we hypothesized that ABHD11-AS1 possibly plays an analogous role in human bladder cancer. We first found that ABHD11-AS1 was up-regulated in bladder cancer tissues and cell lines, and ABHD11-AS1 expression level was positively associated with clinicobiological features. Cell proliferation, cell migration and apoptosis were observed by silencing ABHD11-AS1 and overexpression ABHD11-AS1 caused contrary effects. Taken together, these data suggested that ABHD11-AS1 may be an oncogene and a therapeutic target in bladder cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14945

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer

Abstract